Literature DB >> 24908057

Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease.

Ji Young Hong1, Sang A Lee, Song Yee Kim, Kyung Soo Chung, Sung Woo Moon, Eun Young Kim, Ji Ye Jung, Moo Suk Park, Young Sam Kim, Se Kyu Kim, Joon Chang, Young Ae Kang.   

Abstract

PURPOSE: The impact of pulmonary nontuberculous mycobacterial (pNTM) disease on health-related quality of life (HRQoL) has not received significant attention in the literature. In this study, we compared the HRQoL in patients with pNTM disease and healthy subjects and identified influencing factors using EuroQol 5D (EQ-5D) data.
METHODS: The present study used an age- and sex-matched case-control analysis from a cohort of 85 pNTM patients and 340 participants from a national survey. Baseline EQ-5D utility scores and EQ-5D visual analog scale (VAS) scores were measured in both groups. In patients with pNTM disease, the factors affecting EQ-5D were identified using multiple linear regression analysis.
RESULTS: While the median EQ-5D VAS scores were lower in pNTM patients than in the control subjects (pNTM, 70; control, 80; P < 0.001), the median EQ-5D utility scores were similar in two groups (both, 1.000, P = 0.878). Interestingly, the percentage of subjects reporting problems on the anxiety/depression dimension was higher for patients with pNTM disease (18.8 %) compared with the control subjects (11.5 %, P = 0.07). In multivariate analysis, increasing severity of forced expired volume in one second (FEV1) decline was associated with a significant decrease in EQ-5D scores of pNTM patients.
CONCLUSIONS: This study suggested the EQ-5D may not be useful instrument in pNTM patients due to ceiling effect of EQ-5D and mild disease activity. Patients with pNTM disease tended to report more reduced health status and more problems with anxiety/depression than the healthy controls. Lung function, measured by FEV1, was independently associated with EQ-5D scores in patients with pNTM disease.

Entities:  

Mesh:

Year:  2014        PMID: 24908057     DOI: 10.1007/s11136-014-0727-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  31 in total

Review 1.  EQ-5D: a measure of health status from the EuroQol Group.

Authors:  R Rabin; F de Charro
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

2.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

Review 3.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

Review 4.  Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts.

Authors:  James L Cook
Journal:  Br Med Bull       Date:  2010-10-25       Impact factor: 4.291

5.  Respiratory symptoms, COPD severity, and health related quality of life in a general population sample.

Authors:  Marianne Voll-Aanerud; Tomas M L Eagan; Tore Wentzel-Larsen; Amund Gulsvik; Per S Bakke
Journal:  Respir Med       Date:  2007-12-03       Impact factor: 3.415

6.  Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations.

Authors:  J H Huang; P N Kao; V Adi; S J Ruoss
Journal:  Chest       Date:  1999-04       Impact factor: 9.410

7.  Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease.

Authors:  C-T Huang; Y-J Tsai; H-D Wu; J-Y Wang; C-J Yu; L-N Lee; P-C Yang
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

Review 8.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

9.  Mycobacterium Avium Complex (MAC) Lung Disease in Two Inner City Community Hospitals: Recognition, Prevalence, Co-Infection with Mycobacterium Tuberculosis (MTB) and Pulmonary Function (PF) Improvements After Treatment.

Authors:  Zinobia Khan; Albert Miller; Moses Bachan; Joseph Donath
Journal:  Open Respir Med J       Date:  2010-08-08

10.  Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.

Authors:  Paul Glasziou; Jan Alexander; Elaine Beller; Philip Clarke
Journal:  Health Qual Life Outcomes       Date:  2007-04-27       Impact factor: 3.186

View more
  5 in total

1.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

2.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

Review 3.  Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?

Authors:  Christopher Vinnard; Alyssa Mezochow; Hannah Oakland; Ross Klingsberg; John Hansen-Flaschen; Keith Hamilton
Journal:  Front Microbiol       Date:  2018-11-20       Impact factor: 5.640

4.  The effects of sildenafil on ciliary beat frequency in patients with pulmonary non-tuberculous mycobacteria disease: phase I/II trial.

Authors:  Cedar Fowler; Un-In Wu; Robyn Shaffer; Caroline Smith; Lisa Barnhart; Clare Bryant; Kenneth Olivier; Steven M Holland
Journal:  BMJ Open Respir Res       Date:  2020-03

5.  Psychometric Validation of the EQ-5D-3L in Patients with Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium avium Complex (MAC).

Authors:  Anuj Shah; Xinyi Ng; Ruchit Shah; Caitlyn Solem; Ping Wang; Marko Obradovic
Journal:  Patient Relat Outcome Meas       Date:  2021-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.